중추신경계 치료제 시장 보고서(2026년)

Central nervous system therapeutics are drugs and treatment approaches developed to manage and treat disorders of the brain and spinal cord. These include conditions such as depression, epilepsy, Parkinson's disease, and multiple sclerosis. Their purpose is to restore neurological function, relieve symptoms, and improve patients' quality of life. They encompass pharmaceuticals, biologics, and advanced neurotechnological interventions.

The main drug classes in central nervous system therapeutics include anesthetics, anticonvulsants, antiemetics, central nervous system (CNS) stimulants, pain relievers, and others. Anesthetics are medications that block pain or induce unconsciousness during medical procedures. These therapies are applied across various disease areas, including neurovascular disorders, mental health conditions, degenerative diseases, genetic disorders, substance abuse, autoimmune and inflammatory diseases, CNS trauma, infectious diseases, CNS cancers, and others. They are distributed through channels such as hospital pharmacies, retail pharmacies, and others, and are used in applications including hospitals, clinics, homecare, and other care settings.

Tariffs have impacted the central nervous system therapeutics market by increasing the cost of imported active pharmaceutical ingredients, biologics, and specialized manufacturing equipment, leading to higher production expenses and pricing pressures. Drug classes such as biologics and advanced neurotherapies are most affected, particularly in regions like North America and Europe that depend on global supply chains. These challenges have caused temporary delays in product availability. However, tariffs have also encouraged domestic manufacturing, regional supply chain diversification, and increased investment in local R&D for CNS therapeutics.

The central nervous system therapeutics market research report is one of a series of new reports from The Business Research Company that provides central nervous system therapeutics market statistics, including central nervous system therapeutics industry global market size, regional shares, competitors with a central nervous system therapeutics market share, detailed central nervous system therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the central nervous system therapeutics industry. This central nervous system therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The central nervous system therapeutics market size has grown strongly in recent years. It will grow from $134.99 billion in 2025 to $147.29 billion in 2026 at a compound annual growth rate (CAGR) of 9.1%. The growth in the historic period can be attributed to increasing burden of depression and epilepsy, growing aging population, limited treatment options for degenerative disorders, rising hospitalization rates for cns conditions, expansion of hospital and clinic infrastructure.

The central nervous system therapeutics market size is expected to see strong growth in the next few years. It will grow to $206.68 billion in 2030 at a compound annual growth rate (CAGR) of 8.8%. The growth in the forecast period can be attributed to development of novel neuroprotective agents, growth in biologics and gene-based therapies, increasing investment in neuroscience research, rising adoption of personalized medicine, expanding access to cns treatments in emerging markets. Major trends in the forecast period include rising prevalence of neurological and mental health disorders, growing adoption of combination therapies for cns diseases, increasing focus on long-term disease management and symptom control, expansion of homecare-based cns treatment solutions, improved drug formulations with better blood-brain barrier penetration.

The increasing prevalence of mental health disorders is expected to drive the growth of the central nervous system (CNS) therapeutics market in the coming years. Mental health disorders encompass a broad range of conditions that affect a person's thinking, emotions, behavior, or mood, including depression, anxiety disorders, schizophrenia, and bipolar disorder. The rising prevalence of these disorders is largely attributed to greater exposure to chronic stress, which can disrupt emotional regulation, weaken coping mechanisms, and contribute to conditions such as anxiety, depression, and burnout. CNS therapeutics address mental health disorders by targeting brain chemicals and neural pathways that regulate mood, behavior, and cognition. For instance, in December 2025, according to a report published by Bristol City Council, a UK-based local government authority, 66,815 patients aged 18 and above were recorded on GP practice depression registers in Bristol during 2022-23, representing a 6.0% increase from 2021-22. Therefore, the rising prevalence of mental health disorders is driving the growth of the CNS therapeutics market.

Major companies operating in the CNS therapeutics market are focusing on innovative solutions such as capsid engineering to enhance targeted gene delivery, improve therapeutic efficacy, and optimize blood-brain barrier penetration for neurological disorder treatments. Capsid engineering involves modifying and optimizing the protein shell (capsid) of viral vectors, typically adeno-associated viruses (AAVs), used in gene therapy. For example, in May 2025, Coave Therapeutics S.A., a France-based biotechnology company, launched coAAV CSF-01, a novel AAV for CNS delivery using their proprietary ALIGATER platform. The vector demonstrated significantly enhanced transduction efficiency and safety compared to AAV9. Delivered via intracisternal magna and intracerebroventricular routes, coAAV-CSF-01 achieved 100-fold higher transgene expression in the cortex and 10,000-fold higher expression in the hippocampus at the same dose. Equivalent expression levels to AAV9 were achieved at just one-fifth of the dose, highlighting its superior potency. The vector also showed markedly reduced off-target expression in peripheral organs such as the liver while maintaining a favorable safety profile, including preserved peripheral nerve integrity, underscoring its potential to improve CNS gene therapy outcomes with higher precision and lower systemic risk.

In June 2025, Supernus Pharmaceuticals Inc., a US-based biopharmaceutical company, acquired Sage Therapeutics Inc. for an undisclosed amount. This acquisition allows Supernus to expand its neuroscience portfolio, strengthen its position in the CNS market, and accelerate the development of innovative treatments for depression and other mood disorders. Sage Therapeutics Inc. is a US-based biopharmaceutical company specializing in CNS therapeutics.

Major companies operating in the central nervous system therapeutics market are Biogen Inc., Otsuka Pharmaceutical Co Ltd., UCB S.A., Jazz Pharmaceuticals plc, Supernus Pharmaceuticals Inc., Biohaven Ltd., Acadia Pharmaceuticals Inc., Neumora Therapeutics Inc., Cerevel Therapeutics LLC, Axsome Therapeutics Inc., TauRx Therapeutics Ltd., Autobahn Therapeutics, BrainStorm Cell Therapeutics Inc., Progentos Therapeutics Inc., Tonix Pharmaceuticals Holding Corp., Neuroplast B.V., Assertio Holdings Inc.

North America was the largest region in the central nervous system therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the central nervous system therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the central nervous system therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The central nervous system therapeutics market consists of sales of sodium channel blockers, amphetamines, and neuroprotective agents. Values in this market are 'factory gate' values; that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Central Nervous System Therapeutics Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses central nervous system therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for central nervous system therapeutics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The central nervous system therapeutics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Drug Class: Anesthetics; Anticonvulsants; Antiemetics; Central Nervous System (CNS) Stimulants; Pain Relievers; Other Drug Classes
• 2) By Disease: Neurovascular Diseases; Mental Health; Degenerative Disorders; Genetic Diseases; Substance Abuse Disorders; Autoimmune And Inflammatory Diseases; Central Nervous System (CNS) Trauma; Infectious Diseases; Central Nervous System (CNS) Cancer; Other Diseases
• 3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Other Distribution Channels
• 4) By Application: Hospital; Clinic; Homecare; Other Applications
• Subsegments:
• 1) By Anesthetics: General Anesthetics; Local Anesthetics; Dissociative Anesthetics; Inhalation Anesthetics; Intravenous Anesthetics
• 2) By Anticonvulsants: Sodium Channel Blockers; GABA Enhancers; Calcium Channel Blockers; SV2A Modulators; Mixed Mechanism Agents
• 3) By Antiemetics: Serotonin 5-HT3 Antagonists; Dopamine Antagonists; Neurokinin-1 (NK1) Receptor Antagonists; Antihistamines; Cannabinoids
• 4) By Central Nervous System (CNS) Stimulants: Amphetamines; Methylphenidates; Modafinil and Armodafinil; Caffeine-Based Stimulants; Xanthine Derivatives
• 5) By Pain Relievers: Opioid Analgesics; Antidepressants for Neuropathic Pain; Anticonvulsants for Pain Relief
• 6) By Other Drug Classes: Antipsychotics; Antidepressants; Muscle Relaxants; Sedatives and Hypnotics; Neuroprotective Agents
• Companies Mentioned: Biogen Inc.; Otsuka Pharmaceutical Co Ltd.; UCB S.A.; Jazz Pharmaceuticals plc; Supernus Pharmaceuticals Inc.; Biohaven Ltd.; Acadia Pharmaceuticals Inc.; Neumora Therapeutics Inc.; Cerevel Therapeutics LLC; Axsome Therapeutics Inc.; TauRx Therapeutics Ltd.; Autobahn Therapeutics; BrainStorm Cell Therapeutics Inc.; Progentos Therapeutics Inc.; Tonix Pharmaceuticals Holding Corp.; Neuroplast B.V.; Assertio Holdings Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

• 1.1. Key Market Insights (2020-2035)
• 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
• 1.3. Major Factors Driving the Market
• 1.4. Top Three Trends Shaping the Market

2. Central Nervous System Therapeutics Market Characteristics

• 2.1. Market Definition & Scope
• 2.2. Market Segmentations
• 2.3. Overview of Key Products and Services
• 2.4. Global Central Nervous System Therapeutics Market Attractiveness Scoring And Analysis
  • 2.4.1. Overview of Market Attractiveness Framework
  • 2.4.2. Quantitative Scoring Methodology
  • 2.4.3. Factor-Wise Evaluation
• Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
• 2.4.4. Market Attractiveness Scoring and Interpretation
• 2.4.5. Strategic Implications and Recommendations

3. Central Nervous System Therapeutics Market Supply Chain Analysis

• 3.1. Overview of the Supply Chain and Ecosystem
• 3.2. List Of Key Raw Materials, Resources & Suppliers
• 3.3. List Of Major Distributors and Channel Partners
• 3.4. List Of Major End Users

4. Global Central Nervous System Therapeutics Market Trends And Strategies

• 4.1. Key Technologies & Future Trends
  • 4.1.1 Biotechnology, Genomics & Precision Medicine
  • 4.1.2 Artificial Intelligence & Autonomous Intelligence
  • 4.1.3 Digitalization, Cloud, Big Data & Cybersecurity
  • 4.1.4 Internet Of Things (Iot), Smart Infrastructure & Connected Ecosystems
  • 4.1.5 Industry 4.0 & Intelligent Manufacturing
• 4.2. Major Trends
  • 4.2.1 Rising Prevalence Of Neurological And Mental Health Disorders
  • 4.2.2 Growing Adoption Of Combination Therapies For Cns Diseases
  • 4.2.3 Increasing Focus On Long-Term Disease Management And Symptom Control
  • 4.2.4 Expansion Of Homecare-Based Cns Treatment Solutions
  • 4.2.5 Improved Drug Formulations With Better Blood-Brain Barrier Penetration

5. Central Nervous System Therapeutics Market Analysis Of End Use Industries

• 5.1 Hospitals
• 5.2 Clinics
• 5.3 Homecare Settings
• 5.4 Specialty Neurology Centers
• 5.5 Rehabilitation And Long-Term Care Centers

6. Central Nervous System Therapeutics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Central Nervous System Therapeutics Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

• 7.1. Global Central Nervous System Therapeutics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 7.2. Global Central Nervous System Therapeutics Market Size, Comparisons And Growth Rate Analysis
• 7.3. Global Central Nervous System Therapeutics Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
• 7.4. Global Central Nervous System Therapeutics Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Central Nervous System Therapeutics Total Addressable Market (TAM) Analysis for the Market

• 8.1. Definition and Scope of Total Addressable Market (TAM)
• 8.2. Methodology and Assumptions
• 8.3. Global Total Addressable Market (TAM) Estimation
• 8.4. TAM vs. Current Market Size Analysis
• 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Central Nervous System Therapeutics Market Segmentation

• 9.1. Global Central Nervous System Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Anesthetics, Anticonvulsants, Antiemetics, Central Nervous System (CNS) Stimulants, Pain Relievers, Other Drug Classes
• 9.2. Global Central Nervous System Therapeutics Market, Segmentation By Disease, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Neurovascular Diseases, Mental Health, Degenerative Disorders, Genetic Diseases, Substance Abuse Disorders, Autoimmune And Inflammatory Diseases, Central Nervous System (CNS) Trauma, Infectious Diseases, Central Nervous System (CNS) Cancer, Other Diseases
• 9.3. Global Central Nervous System Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels
• 9.4. Global Central Nervous System Therapeutics Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Hospital, Clinic, Homecare, Other Applications
• 9.5. Global Central Nervous System Therapeutics Market, Sub-Segmentation Of Anesthetics, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• General Anesthetics, Local Anesthetics, Dissociative Anesthetics, Inhalation Anesthetics, Intravenous Anesthetics
• 9.6. Global Central Nervous System Therapeutics Market, Sub-Segmentation Of Anticonvulsants, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Sodium Channel Blockers, GABA Enhancers, Calcium Channel Blockers, SV2A Modulators, Mixed Mechanism Agents
• 9.7. Global Central Nervous System Therapeutics Market, Sub-Segmentation Of Antiemetics, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Serotonin 5-HT3 Antagonists, Dopamine Antagonists, Neurokinin-1 (NK1) Receptor Antagonists, Antihistamines, Cannabinoids
• 9.8. Global Central Nervous System Therapeutics Market, Sub-Segmentation Of Central Nervous System (CNS) Stimulants, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Amphetamines, Methylphenidates, Modafinil and Armodafinil, Caffeine-Based Stimulants, Xanthine Derivatives
• 9.9. Global Central Nervous System Therapeutics Market, Sub-Segmentation Of Pain Relievers, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Opioid Analgesics, Antidepressants for Neuropathic Pain, Anticonvulsants for Pain Relief
• 9.10. Global Central Nervous System Therapeutics Market, Sub-Segmentation Of Other Drug Classes, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Antipsychotics, Antidepressants, Muscle Relaxants, Sedatives and Hypnotics, Neuroprotective Agents

10. Central Nervous System Therapeutics Market Regional And Country Analysis

• 10.1. Global Central Nervous System Therapeutics Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• 10.2. Global Central Nervous System Therapeutics Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Central Nervous System Therapeutics Market

• 11.1. Asia-Pacific Central Nervous System Therapeutics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific Central Nervous System Therapeutics Market, Segmentation By Drug Class, Segmentation By Disease, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Central Nervous System Therapeutics Market

• 12.1. China Central Nervous System Therapeutics Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 12.2. China Central Nervous System Therapeutics Market, Segmentation By Drug Class, Segmentation By Disease, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Central Nervous System Therapeutics Market

• 13.1. India Central Nervous System Therapeutics Market, Segmentation By Drug Class, Segmentation By Disease, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Central Nervous System Therapeutics Market

• 14.1. Japan Central Nervous System Therapeutics Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 14.2. Japan Central Nervous System Therapeutics Market, Segmentation By Drug Class, Segmentation By Disease, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Central Nervous System Therapeutics Market

• 15.1. Australia Central Nervous System Therapeutics Market, Segmentation By Drug Class, Segmentation By Disease, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Central Nervous System Therapeutics Market

• 16.1. Indonesia Central Nervous System Therapeutics Market, Segmentation By Drug Class, Segmentation By Disease, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Central Nervous System Therapeutics Market

• 17.1. South Korea Central Nervous System Therapeutics Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 17.2. South Korea Central Nervous System Therapeutics Market, Segmentation By Drug Class, Segmentation By Disease, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Central Nervous System Therapeutics Market

• 18.1. Taiwan Central Nervous System Therapeutics Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 18.2. Taiwan Central Nervous System Therapeutics Market, Segmentation By Drug Class, Segmentation By Disease, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Central Nervous System Therapeutics Market

• 19.1. South East Asia Central Nervous System Therapeutics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 19.2. South East Asia Central Nervous System Therapeutics Market, Segmentation By Drug Class, Segmentation By Disease, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Central Nervous System Therapeutics Market

• 20.1. Western Europe Central Nervous System Therapeutics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 20.2. Western Europe Central Nervous System Therapeutics Market, Segmentation By Drug Class, Segmentation By Disease, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Central Nervous System Therapeutics Market

• 21.1. UK Central Nervous System Therapeutics Market, Segmentation By Drug Class, Segmentation By Disease, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Central Nervous System Therapeutics Market

• 22.1. Germany Central Nervous System Therapeutics Market, Segmentation By Drug Class, Segmentation By Disease, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Central Nervous System Therapeutics Market

• 23.1. France Central Nervous System Therapeutics Market, Segmentation By Drug Class, Segmentation By Disease, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Central Nervous System Therapeutics Market

• 24.1. Italy Central Nervous System Therapeutics Market, Segmentation By Drug Class, Segmentation By Disease, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Central Nervous System Therapeutics Market

• 25.1. Spain Central Nervous System Therapeutics Market, Segmentation By Drug Class, Segmentation By Disease, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Central Nervous System Therapeutics Market

• 26.1. Eastern Europe Central Nervous System Therapeutics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 26.2. Eastern Europe Central Nervous System Therapeutics Market, Segmentation By Drug Class, Segmentation By Disease, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Central Nervous System Therapeutics Market

• 27.1. Russia Central Nervous System Therapeutics Market, Segmentation By Drug Class, Segmentation By Disease, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Central Nervous System Therapeutics Market

• 28.1. North America Central Nervous System Therapeutics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 28.2. North America Central Nervous System Therapeutics Market, Segmentation By Drug Class, Segmentation By Disease, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Central Nervous System Therapeutics Market

• 29.1. USA Central Nervous System Therapeutics Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 29.2. USA Central Nervous System Therapeutics Market, Segmentation By Drug Class, Segmentation By Disease, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Central Nervous System Therapeutics Market

• 30.1. Canada Central Nervous System Therapeutics Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 30.2. Canada Central Nervous System Therapeutics Market, Segmentation By Drug Class, Segmentation By Disease, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Central Nervous System Therapeutics Market

• 31.1. South America Central Nervous System Therapeutics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 31.2. South America Central Nervous System Therapeutics Market, Segmentation By Drug Class, Segmentation By Disease, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Central Nervous System Therapeutics Market

• 32.1. Brazil Central Nervous System Therapeutics Market, Segmentation By Drug Class, Segmentation By Disease, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Central Nervous System Therapeutics Market

• 33.1. Middle East Central Nervous System Therapeutics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 33.2. Middle East Central Nervous System Therapeutics Market, Segmentation By Drug Class, Segmentation By Disease, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Central Nervous System Therapeutics Market

• 34.1. Africa Central Nervous System Therapeutics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 34.2. Africa Central Nervous System Therapeutics Market, Segmentation By Drug Class, Segmentation By Disease, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Central Nervous System Therapeutics Market Regulatory and Investment Landscape

36. Central Nervous System Therapeutics Market Competitive Landscape And Company Profiles

• 36.1. Central Nervous System Therapeutics Market Competitive Landscape And Market Share 2024
  • 36.1.1. Top 10 Companies (Ranked by revenue/share)
• 36.2. Central Nervous System Therapeutics Market - Company Scoring Matrix
  • 36.2.1. Market Revenues
  • 36.2.2. Product Innovation Score
  • 36.2.3. Brand Recognition
• 36.3. Central Nervous System Therapeutics Market Company Profiles
  • 36.3.1. Biogen Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.2. Otsuka Pharmaceutical Co Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.3. UCB S.A. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.4. Jazz Pharmaceuticals plc Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.5. Supernus Pharmaceuticals Inc. Overview, Products and Services, Strategy and Financial Analysis

37. Central Nervous System Therapeutics Market Other Major And Innovative Companies

• Biohaven Ltd., Acadia Pharmaceuticals Inc., Neumora Therapeutics Inc., Cerevel Therapeutics LLC, Axsome Therapeutics Inc., TauRx Therapeutics Ltd., Autobahn Therapeutics, BrainStorm Cell Therapeutics Inc., Progentos Therapeutics Inc., Tonix Pharmaceuticals Holding Corp., Neuroplast B.V.

38. Global Central Nervous System Therapeutics Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Central Nervous System Therapeutics Market

40. Central Nervous System Therapeutics Market High Potential Countries, Segments and Strategies

• 40.1 Central Nervous System Therapeutics Market In 2030 - Countries Offering Most New Opportunities
• 40.2 Central Nervous System Therapeutics Market In 2030 - Segments Offering Most New Opportunities
• 40.3 Central Nervous System Therapeutics Market In 2030 - Growth Strategies
  • 40.3.1 Market Trend Based Strategies
  • 40.3.2 Competitor Strategies

41. Appendix

• 41.1. Abbreviations
• 41.2. Currencies
• 41.3. Historic And Forecast Inflation Rates
• 41.4. Research Inquiries
• 41.5. The Business Research Company
• 41.6. Copyright And Disclaimer